Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:CUENASDAQ:MRSNNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriaCell Therapeutics$4.09-8.3%$4.49$3.00▼$45.45$15.17M1.71193,659 shs58,227 shsCUECue Biopharma$1.00-3.3%$1.24$0.45▼$2.26$63.10M1.88446,528 shs60,126 shsMRSNMersana Therapeutics$0.45+0.7%$0.56$0.40▼$4.71$55.85M1.672.36 million shs1.72 million shsUNCYUnicycive Therapeutics$0.64-1.2%$0.59$0.20▼$1.60$65.97M2.261.40 million shs547,677 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriaCell Therapeutics-8.30%+5.41%-8.30%-49.21%-90.43%CUECue Biopharma-3.29%+3.22%-24.54%-1.38%-46.45%MRSNMersana Therapeutics+0.74%-4.48%-15.96%-72.34%-89.51%UNCYUnicycive Therapeutics-1.17%+6.86%+3.03%-5.16%-58.18%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriaCell Therapeutics1.7478 of 5 stars3.54.00.00.00.00.00.6CUECue Biopharma4.0391 of 5 stars3.55.00.04.70.00.80.6MRSNMersana Therapeutics3.592 of 5 stars3.52.00.04.10.03.30.0UNCYUnicycive Therapeutics2.2499 of 5 stars3.63.00.00.00.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriaCell Therapeutics 3.00Buy$32.00682.40% UpsideCUECue Biopharma 3.00Buy$4.75376.86% UpsideMRSNMersana Therapeutics 3.00Buy$4.00792.66% UpsideUNCYUnicycive Therapeutics 3.25Buy$5.33739.10% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, UNCY, CUE, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/3/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.002/6/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/3/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $32.001/29/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.001/10/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.00 ➝ $4.001/8/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/ACUECue Biopharma$9.53M6.62N/AN/A$0.82 per share1.21MRSNMersana Therapeutics$40.50M1.38N/AN/A$0.31 per share1.45UNCYUnicycive Therapeutics$680K97.02N/AN/A($0.11) per share-5.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%6/13/2025 (Estimated)CUECue Biopharma-$50.73M-$0.90N/AN/AN/A-468.02%-156.38%-88.07%3/26/2025 (Estimated)MRSNMersana Therapeutics-$171.67M-$0.56N/AN/AN/A-214.20%-401.37%-38.61%5/8/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$0.97N/AN/AN/AN/AN/A-29.88%3/27/2025 (Estimated)Latest BCTX, UNCY, CUE, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/14/2025N/ACUECue Biopharma-$0.17N/AN/AN/AN/AN/A3/27/2025N/AUNCYUnicycive Therapeutics-$0.13N/AN/AN/AN/AN/A3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/A3/3/2025Q4 2024MRSNMersana Therapeutics-$0.16-$0.11+$0.05-$0.11$7.71 million$16.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriaCell TherapeuticsN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriaCell TherapeuticsN/A1.651.65CUECue Biopharma0.052.222.22MRSNMersana Therapeutics13.352.352.35UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriaCell Therapeutics15.42%CUECue Biopharma35.04%MRSNMersana Therapeutics93.92%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipBCTXBriaCell Therapeutics5.73%CUECue Biopharma12.26%MRSNMersana Therapeutics11.80%UNCYUnicycive Therapeutics24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableCUECue Biopharma6063.35 million55.58 millionOptionableMRSNMersana Therapeutics150124.63 million108.96 millionOptionableUNCYUnicycive Therapeutics9103.80 million78.78 millionNot OptionableBCTX, UNCY, CUE, and MRSN HeadlinesRecent News About These CompaniesUnicycive Therapeutics (UNCY) to Release Earnings on ThursdayMarch 25 at 2:36 AM | americanbankingnews.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest UpdateMarch 15, 2025 | marketbeat.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 2% - Should You Sell?March 8, 2025 | marketbeat.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360February 20, 2025 | globenewswire.comBuy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill BurdenJanuary 29, 2025 | markets.businessinsider.comUnicycive highlights challenges in phosphate managementJanuary 28, 2025 | msn.comUnicycive announces publication of patient perspectives on phosphate managementJanuary 28, 2025 | markets.businessinsider.comHere's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn SituationJanuary 28, 2025 | finance.yahoo.comUnicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney DiseaseJanuary 28, 2025 | quiverquant.comUnicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological ScienceJanuary 28, 2025 | globenewswire.comPositive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue ForecastsJanuary 9, 2025 | markets.businessinsider.comUnicycive Therapeutics announces publication of OLC dose escalation dataJanuary 8, 2025 | markets.businessinsider.comUnicycive Therapeutics Publishes Positive Phase 1 Study Data on Oxylanthanum Carbonate in Clinical and Translational ScienceJanuary 7, 2025 | quiverquant.comUnicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational ScienceJanuary 7, 2025 | globenewswire.comUnicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical TherapeuticsDecember 17, 2024 | markets.businessinsider.comBreakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)November 28, 2024 | uk.finance.yahoo.comUnicycive Therapeutics Inc’s Stock Drama: Could This Be a Game-Changer for UNCY Investors?November 28, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCTX, UNCY, CUE, and MRSN Company DescriptionsBriaCell Therapeutics NASDAQ:BCTX$4.09 -0.37 (-8.30%) Closing price 03/25/2025 03:59 PM EasternExtended Trading$4.32 +0.23 (+5.50%) As of 03/25/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Cue Biopharma NASDAQ:CUE$1.00 -0.03 (-3.29%) As of 03/25/2025 04:00 PM EasternCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Mersana Therapeutics NASDAQ:MRSN$0.45 +0.00 (+0.74%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.45 0.00 (-0.47%) As of 03/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Unicycive Therapeutics NASDAQ:UNCY$0.64 -0.01 (-1.17%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.64 0.00 (-0.09%) As of 03/25/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
